Covaxin has tolerable safety: Lancet

The vaccine was well tolerated in all dose groups with no vaccine-related adverse events.
Ruchika Chitravanshi reports.

Bharat Biotech's Covaxin, which has courted controversy over its restricted use approval despite the lack of efficacy data, has shown tolerable safety outcomes and enhanced immune response in the phase one study, said a paper published in the British medical journal Lancet.

Sharing the interim findings, the paper said that the vaccine was well tolerated in all dose groups with no vaccine-related adverse events. The most common adverse event was pain at the injection site, followed by headache, fatigue and fever.

'The overall incidence of solicited local and systemic adverse events in this study was 14-21 per cent in all vaccine-treated groups, which is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates,' the paper said.

It also noted that the study population did not have ethnic diversity and most of the participants were men, 'further underscoring the importance of assessing BBV152 (the code name for the vaccine) in other populations'.

The study was conducted with volunteers from diverse geographic locations within India, enrolling 375 participants across 11 hospitals.

The enrolment, which occurred during the national lockdown and during a period when Covid cases were surging in the country, posed an operational challenge for the study. However, the participation retention rate was around 97 per cent.

'Because this is an interim report, we are not reporting any data on the persistence of vaccine-induced antibody responses or long-term safety outcomes. The results reported here do not permit efficacy assessments.'

'With several reports questioning the efficacy of SARS-CoV-2 vaccines against antigenically divergent strains, we report neutralising responses to homologous and heterologous strains,' the paper added.

Before granting the recommendation to proceed with the enrolment of other cohorts, masked safety data was reviewed by the data safety monitoring board to ensure no operational bias was introduced, the study mentioned.

Between July 13-30, 897 individuals were screened and 375 were enrolled. Of the 522 who were excluded, 133 participants were left out because they were positive for SARS-CoV-2, and the other 153 weren't considered because of abnormal laboratory values.